Clinical Trial Update: Dutasteride in Treating Patients With Recurrent Prostate Cancer That Did Not Respond to Androgen-Deprivation Therapy [Phase 2]

View source ↗

Summary

Phase 2 clinical trial of dutasteride for recurrent prostate cancer unresponsive to androgen-deprivation therapy has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• DUTASTERIDE (Dutasteride)

Snippet

Sponsor: Roswell Park Cancer Institute | Conditions: Prostate Cancer | Phase 2 | Status: COMPLETED